Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines
Go back to Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines| Novavax, Inc. (NASDAQ: NVAX) | Delayed: 9.36 +0.36 (4.00%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.00 | 52 Week High | $9.23 | |||
| Open | $8.81 | 52 Week Low | $1.16 | |||
| Day High | $9.59 | P/E | N/A | |||
| Day Low | $8.81 | EPS | $-0.30 | |||
| Volume | 1,392,497 | |||||
